Aurinia Pharmaceuticals (AUPH) Capital Expenditures (2020 - 2026)

Aurinia Pharmaceuticals has reported Capital Expenditures for 7 years, with the latest figure at $39000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 129.41% year-over-year to $39000.0; the trailing twelve-month figure through Mar 2026 stood at $274000.0 (down 4.2% YoY), and the FY2025 full-year result was $252000.0, down 10.32% from the prior year.
• Capital Expenditures for Q1 2026 stood at $39000.0, down from $72000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $347000.0 in Q1 2023, with the low at -$105000.0 in Q3 2023.
• Historically, Capital Expenditures has averaged $93058.8 across 5 years, with a median of $72000.0 in 2025.
• The largest YoY upside for Capital Expenditures was 353.85% in 2023 against a maximum downside of 362.5% in 2023.
• Aurinia Pharmaceuticals' Capital Expenditures stood at $134000.0 in 2022, then jumped by 123.13% to $299000.0 in 2023, then sank by 81.27% to $56000.0 in 2024, then gained by 28.57% to $72000.0 in 2025, then sank by 45.83% to $39000.0 in 2026.
• The last three Capital Expenditures figures came in at $39000.0 (Q1 2026), $72000.0 (Q4 2025), and $65000.0 (Q3 2025), per Business Quant data.